Genome Editing of MSCs as a Platform for Cell Therapy
The rapid growing of genome editing technology leads to an optimistic expectation for the treatment of many incurable diseases. The core of genome editing relies on DNA-repairing processes which occur independently in each cell, thus generating a mix of genetic variation cells. Here, we describe the protocol of using mesenchymal stem cells as a platform to generate high purity of ZFN-edited patients’ cell clones which may be useful in conjunction with therapeutic cell conversion and reprograming.
Key wordsGenome editing Zinc-finger nuclease (ZFN) Mesenchymal stem cells Homologous recombination
- 4.Manotham K, Chattong S, Setpakdee A (2015) Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones. J Biomed Sci 26:22–25Google Scholar
- 14.Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A et al (2007) Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 40:785–791CrossRefPubMedGoogle Scholar